Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS31-164 in HER2 Expressing Solid Tumors
NCT02386501Phase 2Completed
- Sponsor
- Advaxis, Inc.
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of daznelimgene lisbac in HER2-positive solid tumor (HER2+), sponsored by Advaxis, Inc.. Started Sep 2015; status: completed.
02
Drugs
daznelimgene lisbac
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT02386501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386501.